Light chain deposition disease: Novel biological insights and treatment advances

International Journal of Laboratory Hematology

Volumn 34, Issue 4, 2012, Pages 347-355

  Jimenez Zepeda, V H ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Bortezomib; Light chain deposition disease; Multiple myeloma; Thalidomide and lenalidomide

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; STEROID; THALIDOMIDE;

AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DIARRHEA; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG MEGADOSE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIGHT CHAIN DEPOSITION DISEASE; LIVER DISEASE; LUNG DISEASE; MAINTENANCE THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCREENING TEST; SURVIVAL RATE; TREATMENT RESPONSE;

BORONIC ACIDS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PYRAZINES;

EID: 84862896883     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2012.01419.x     Document Type: Review

References (55)

1. McKenna R.W., Kyle RA., Kuehl W.M., Grogan T.M., Harris N.L. & Coupland R.W. (2008) Plasma Cell Neoplasms in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer, Lyon.
2. Randall R.E., Williamson W.C. Jr, Mullinax F., Tung M.Y. & Still W.J. (1976) Manifestations of systemic light chain deposition. The American Journal of Medicine 60, 293-299.
3. Buxbaum J. & Gallo G. (1999) Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematology/Oncology Clinics of North America 13, 1235-1248.
4. Sanders P.W. & Herrera G.A. (1993) Monoclonal immunoglobulin light chain-related renal diseases. Seminars in Nephrology 13, 324-341.
5. Preud'homme J.L., Ganeval D., Grunfeld J.P., Striker L. & Brouet J.C. (1988) Immunoglobulin synthesis in primary and myeloma amyloidosis. Clinical and Experimental Immunology 73, 389-394.
6. Pozzi C., D'Amico M., Fogazzi G.B., Curioni S., Ferrario F., Pasquali S., Quattrocchio G., Rollino C., Segagni S. & Locatelli F. (2003) Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. American Journal of Kidney Diseases 42, 1154-1163.
7. Pozzi C. & Locatelli F. (2002) Kidney and liver involvement in monoclonal light chain disorders. Seminars in Nephrology 22, 319-330.
8. Ronco P.M., Alyanakian M.A., Mougenot B. & Aucouturier P. (2001) Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. Journal of the American Society of Nephrology 12, 1558-1565.
9. Ronco P., Plaisier E., Mougenot B. & Aucouturier P. (2006) Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clinical Journal of American Society of Nephrology 1, 1342-1350.
10. Lin J., Markowitz G.S., Valeri A.M., Kambham N., Sherman W.H., Appel G.B. & D'Agati V.D. (2001) Renal monoclonal immunoglobulin deposition disease: the disease spectrum. Journal of the American Society of Nephrology 12, 1482-1492.
11. Herrera G.A. (1994) Light chain deposition disease (nodular glomerulopathy, kappa light chain deposition disease): a case report. Ultrastructural Pathology 18, 119-126.
12. Herrera G.A., Joseph L., Gu X., Hough A. & Barlogie B. (2004) Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Archives of Pathology and Laboratory Medicine 128, 875-879.
13. Masai R., Wakui H., Togashi M., Maki N., Ohtani H., Komatsuda A. & Sawada K. (2009) Clinicopathological features and prognosis in immunoglobulin light and heavy chain deposition disease. Clinical Nephrology 71, 9-20.
14. Brioli A., Zamagni E., Pasquali S., Tosi P., Tacchetti P., Perrone G., Pantani L., Petrucci A., Zannetti B.A., Baccarani M. & Cavo M. (2012) Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. Bone Marrow Transplantation doi:
15. Rostagno A., Frizzera G., Ylagan L., Kumar A., Ghiso J. & Gallo G. (2002) Tumoral non-amyloidotic monoclonal immunoglobulin light chain deposits ('aggregoma'): presenting feature of B-cell dyscrasia in three cases with immunohistochemical and biochemical analyses. British Journal of Haematology 119, 62-69.
16. Croitoru A.G., Hytiroglou P., Schwartz M.E. & Saxena R. (2006) Liver transplantation for liver rupture due to light chain deposition disease: a case report. Seminars in Liver Disease 26, 298-303.
17. Fabbian F., Stabellini N., Sartori S., Tombesi P., Aleotti A., Bergami M., Uggeri S., Galdi A., Molino C. & Catizone L. (2007) Light chain deposition disease presenting as paroxysmal atrial fibrillation: a case report. Journal of Medical Case Reports 1, 187.
18. Gallo G., Goni F., Boctor F., Vidal R., Kumar A., Stevens F.J., Frangione B. & Ghiso J. (1996) Light chain cardiomyopathy. Structural analysis of the light chain tissue deposits. The American Journal of Pathology 148, 1397-1406.
19. Koopman P., Van Dorpe J., Maes B. & Dujardin K. (2009) Light chain deposition disease as a rare cause of restrictive cardiomyopathy. Acta Cardiologica 64, 821-824.
20. Ganeval D., Noel L.H., Preud'homme J.L., Droz D. & Grunfeld J.P. (1984) Light-chain deposition disease: its relation with AL-type amyloidosis. Kidney International 26, 1-9.
21. Colombat M., Gounant V., Mal H., Callard P. & Milleron B. (2007) Light chain deposition disease involving the airways: diagnosis by fibreoptic bronchoscopy. European Respiratory Journal 29, 1057-1060.
22. Khoor A., Myers J.L., Tazelaar H.D. & Kurtin P.J. (2004) Amyloid-like pulmonary nodules, including localized light-chain deposition: clinicopathologic analysis of three cases. American Journal of Clinical Pathology 121, 200-204.
23. Morinaga S., Watanabe H., Gemma A., Mukai K., Nakajima T., Shimosato Y., Goya T. & Shinoda T. (1987) Plasmacytoma of the lung associated with nodular deposits of immunoglobulin. The American Journal of Surgical Pathology 11, 989-995.
24. Piard F., Yaziji N., Jarry O., Assem M., Martin L., Bernard A., Jacquot J.P. & Justrabo E. (1998) Solitary plasmacytoma of the lung with light chain extracellular deposits: a case report and review of the literature. Histopathology 32, 356-361.
25. Grassi M.P., Clerici F., Perin C., Borella M., Gendarini A., Quattrini A., Nemni R. & Mangoni A. (1998) Light chain deposition disease neuropathy resembling amyloid neuropathy in a multiple myeloma patient. Italian Journal of Neurological Sciences 19, 229-233.
26. Gandhi D., Wee R. & Goyal M. (2003) CT and MR imaging of intracerebral amyloidoma: case report and review of the literature. AJNR American Journal of Neuroradiology 24, 519-522.
27. Popovic M., Tavcar R., Glavac D., Volavsek M., Pirtosek Z. & Vizjak A. (2007) Light chain deposition disease restricted to the brain: the first case report. Human Pathology 38, 179-184.
28. Laeng R.H., Altermatt H.J., Scheithauer B.W. & Zimmermann D.R. (1998) Amyloidomas of the nervous system: a monoclonal B-cell disorder with monotypic amyloid light chain lambda amyloid production. Cancer 82, 362-374.
29. Went P., Ascani S., Strom E., Brorson S.H., Musso M., Zinzani P.L., Falini B., Dirnhofer S. & Pileri S. (2004) Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. The Lancet Oncology 5, 381-383.
30. Katzmann J.A., Kyle R.A., Benson J., Larson D.R., Snyder M.R., Lust J.A., Rajkumar S.V. & Dispenzieri A. (2009) Screening panels for detection of monoclonal gammopathies. Clinical Chemistry 55, 1517-1522.
31. Katzmann J.A., Clark R.J., Abraham R.S., Bryant S., Lymp J.F., Bradwell A.R. & Kyle R.A. (2002) Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clinical Chemistry 48, 1437-1444.
32. Dispenzieri A., Lacy M.Q., Katzmann J.A., Rajkumar S.V., Abraham R.S., Hayman S.R., Kumar S.K., Clark R., Kyle R.A., Litzow M.R., Inwards D.J., Ansell S.M., Micallef I.M., Porrata L.F., Elliott M.A., Johnston P.B., Greipp P.R., Witzig T.E., Zeldenrust S.R., Russell S.J., Gastineau D. & Gertz MA. (2006) Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 107, 3378-3383.
33. Ozsan G.H. & Dispenzieri A. (2011) Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias. Expert Review of Clinical Immunology 7, 65-73.
34. Ronco P., Plaisier E. & Aucouturier P. (2011) Monoclonal immunoglobulin light and heavy chain deposition diseases: molecular models of common renal diseases. Contributions to Nephrology 169, 221-231.
35. Michopoulos S., Petraki K., Petraki C. & Dimopoulos M.A. (2002) Light chain deposition disease of the liver without renal involvement in a patient with multiple myeloma related to liver failure and rapid fatal outcome. Digestive Diseases and Sciences 47, 730-734.
36. Kim H.J., Park E., Lee T.J., Do J.H., Cha Y.J. & Lee S.J. (2012) A case of isolated light chain deposition disease in the duodenum. Journal of Korean Medical Science 27, 207-210.
37. Rajkumar S.V. (2011) Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. American Journal of Hematology 86, 57-65.
38. Gharwan H. & Truica C.I. (2011) Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure. Medical Oncology [Epub ahead of print]. (Northwood, London, England).
39. Lorenz E.C., Gertz M.A., Fervenza F.C., Dispenzieri A., Lacy M.Q., Hayman S.R., Gastineau D.A. & Leung N. (2008) Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrology, Dialysis, Transplantation 23, 2052-2057.
40. Jimenez Zepeda V.F.N., Winter A., Reece D., Trudel S., Chen C., Rabea A. & Kukreti V. (2010) Light Chain Deposition Disease: impact of stem cell transplant on Hematological Response achievement. Blood 116, 2303. (Abstract 4600).
41. Telio D., Shepherd J., Forrest D., Zypchen L., Barnett M., Nevill T. & Song K.W. (2012) High-dose melphalan followed by ASCT has favorable safety and efficacy in selected patients with light chain deposition disease and light and heavy chain deposition disease. Bone Marrow Transplantation 47, 453-455.
42. Fineschi S., Reith W., Guerne P.A., Dayer J.M. & Chizzolini C. (2006) Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts. FASEB Journal 20, 562-564.
43. Keeling J. & Herrera G.A. (2007) The mesangium as a target for glomerulopathic light and heavy chains: pathogenic considerations in light and heavy chain-mediated glomerular damage. Contributions to Nephrology 153, 116-134.
44. Ludwig H., Drach J., Graf H., Lang A. & Meran J.G. (2007) Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 92, 1411-1414.
45. Minarik J., Scudla V., Tichy T., Pika T., Bacovsky J., Lochman P. & Zadrazil J. (2012) Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement. Leukemia and Lymphoma 330, 330-331.
46. Kastritis E., Migkou M., Gavriatopoulou M., Zirogiannis P., Hadjikonstantinou V. & Dimopoulos M.A. (2009) Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica 94, 300-302.
47. Fujita H., Hishizawa M., Sakamoto S., Kondo T., Kadowaki N., Ishikawa T., Itoh J., Fukatsu A., Uchiyama T. & Takaori-Kondo A. (2011) Durable hematological response and improvement of nephrotic syndrome on thalidomide therapy in a patient with refractory light chain deposition disease. International Journal of Hematology 93, 673-676.
48. Weisel K.C., Bockeler M., Bianchi L., Terracciano L.M., Mayer F. & Kanz L. (2009) Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide. International Journal of Hematology 89, 91-94.
49. Leung N., Lager D.J., Gertz M.A., Wilson K., Kanakiriya S. & Fervenza F.C. (2004) Long-term outcome of renal transplantation in light-chain deposition disease. American Journal of Kidney Diseases 43, 147-153.
50. Short A.K., O'Donoghue D.J., Riad H.N., Short C.D. & Roberts I.S. (2001) Recurrence of light chain nephropathy in a renal allograft. A case report and review of the literature. American Journal of Nephrology 21, 237-240.
51. Kaposztas Z., Kahan B.D., Katz S.M., Van Buren C.T. & Cherem L. (2009) Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report. Transplantation Proceedings 41, 4407-4410.
52. Kuypers D.R., Lerut E., Claes K., Evenepoel P. & Vanrenterghem Y. (2007) Recurrence of light chain deposit disease after renal allograft transplantation: potential role of rituximab? Transplant International 20, 381-385.
53. Gertz M.A. (2012) Managing light chain deposition disease. Leukemia and Lymphoma 53, 183-184.
54. Ronco P.M., Mougenot B., Touchard G., Preud'homme J.L. & Aucouturier P. (1995) Renal involvement in hematological disorders: monoclonal immunoglobulins and nephropathy. Current Opinion in Nephrology and Hypertension 4, 130-138.
55. Droz D., Noel L.H., Carnot F., Degos F., Ganeval D. & Grunfeld J.P. (1984) Liver involvement in nonamyloid light chain deposits disease. Laboratory Investigation 50, 683-689.